Immunomedics Constructs New Humanized Antibody for B-cell Mediated Cancer and Autoimmune Diseases Immunomedics, Inc. reported the issuance of U.S. Patent 8,486,395 with expiration on August 2, 2024. The new patent covers additional claims for the patent family, “Anti-CD19 Antibodies.” The allowed claims protect our new, proprietary humanized hA19 antibody and cover its use for the treatment of B-cell lymphoma, chronic lymphocytic leukemia or acute lymphocytic leukemia. [Immunomedics, Inc.] Press Release Researcher Finds Way to Convert Blood Cells into Autoimmune Disease Treatment Cells from one’s own blood could be converted into a treatment for autoimmune diseases, like rheumatoid arthritis and Crohn’s disease, based on the discovery of a Purdue University researcher. Chang Kim, a professor of comparative pathobiology, has created a way to direct the differentiation of T-cells, a white blood cell that is a key player in the body’s immune system. The method uses naïve T-cells, immature cells from which all T-cells develop, and induces them to become suppressive T-cells that block the development of painful inflammation associated with autoimmune diseases. [Purdue University] Press Release ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors ARIAD Pharmaceuticals, Inc. announced the appointment of Sarah J. Schlesinger, M.D., senior attending physician and associate professor of clinical investigation in the Laboratory of Cellular Physiology and Immunology at The Rockefeller University, to its Board of Directors. Dr. Schlesinger is a prominent clinical investigator and immunologist who has spent more than 20 years working in the field of cellular immunity, including as clinical director of the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. [ARIAD Pharmaceuticals, Inc.] Press Release NeoStem Advances Autoimmune Platform through UCSF Collaboration NeoStem, Inc. announced that the Company has executed agreements with the University of California, San Francisco (UCSF) and the laboratories of Jeffrey Bluestone, PhD, and Qizhi Tang, PhD, to collaborate on the development of human regulatory T cells for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection. [NeoStem, Inc.] Press Release From our sponsor: View immunology lectures, protocols and other resources on the Human Immunology Portal. |